← All Allovir, INC filings

Allovir, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

ALVR
Allovir, INC
10-K: Kalaris Therapeutics Reports 2025 Losses, Advances Retinal Drug TH103
Kalaris Therapeutics, a clinical-stage biopharmaceutical company, reported significant net losses in 2025 while advancing its lead product candidate, TH103, for retinal diseases with promising early clinical data.
ALVR
Allovir, INC
10-K: AlloVir to Merge with Kalaris Therapeutics After Discontinued Trials, Aims for KLRS Ticker
AlloVir plans to merge with Kalaris Therapeutics following the discontinuation of its Phase 3 trials, seeking to maximize shareholder value and trade under the ticker symbol KLRS upon completion.
ALVR
Allovir, INC
10-K: AlloVir Discontinues Phase 3 Trials, Initiates Strategic Review Amidst Financial Restructuring
AlloVir halts Phase 3 trials for posoleucel, initiates strategic review, and reduces workforce by 95% to preserve capital.